Avitide, Inc., a Lebanon, New Hampshire-based biotech company dedicated to the discovery and development of custom affinity purification solutions for the biopharmaceutical industry, closed their Series A financing.
The amount of the funding ws not disclosed.
The round was led by Borealis Ventures, with participation from SV Life Sciences, Polaris Venture Partners, OrbiMed Advisors, and Angeli Parvi.
Managing Partners Phil Ferneau (Borealis Ventures) and Michael Ross (SV Life Sciences) joined Avitide’s Board of Directors.
Co-founded by Tillman Gerngross, Errik Anderson, Kevin Isett, and Jonathan Sheller, Avitide has developed a technology platform designed to discover and develop affinity purification products designed to improve the fundamental timeframes and economics of commercial bioprocessing.
The company intends to use the capital for further development of its platform and continued commercial development of affinity resins for monoclonal antibodies, therapeutic proteins, and recombinant vaccines.